Predict your next investment

Venture Capital
pci.upenn.edu

See what CB Insights has to offer

Investments

10

About PCI Ventures

PCI Ventures (PCIV) at the University of Pennsylvania is dedicated to supporting technology commercialization within the Penn community. Since 2010, PCIV has worked with over 200 faculty and staff members to form and launch new companies based on selected inventions and innovative technologies.

PCI Ventures Headquarter Location

3600 Civic Center Boulevard 9th Floor

Philadelphia, Pennsylvania, 19104,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest PCI Ventures News

Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer

Feb 13, 2020

Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture capital firm Kairos Ventures. The preclinical stage company was founded in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. It was founded by researchers Ravi K. Amaravadi and Jeffrey D. Winkler from the University of Pennsylvania’s Abramson Cancer Center and the Department of Chemistry. Jim Demetriades – founder and Managing Partner of Kairos Ventures said: “Pinpoint has developed best-in-class compounds with unprecedented therapeutic potential and we are thrilled to support their efforts as they develop these novel drug-candidates for treatment of colon cancer, pancreatic cancer, melanoma , and other major unmet needs in oncology.” According to Pinpoint Therapeutics, autophagy is a well-established mechanism of cancer cell survival and drug resistance. The biopharma company claimed that its compounds target a recently discovered enzyme in the autophagy pathway called PPT1, which is expressed highly across most cancers. Pinpoint Therapeutics believes that these inhibitors could be applied to a wide range of cancers alone or in combination with other treatments to overcome the challenge of therapy resistance. The pharma start-up will develop autophagy inhibitors into clinical drugs for evaluating in a variety of treatment-refractory cancers . Christian Peters – CEO of Pinpoint Therapeutics said: “This initial round of financing will allow us to develop a new approach to drugging autophagy, which until now seemed difficult to target in cancer. The activity of PPT1 inhibitors in cancer models has not been seen before in the autophagy space.” Related posts

PCI Ventures Investments

10 Investments

PCI Ventures has made 10 investments. Their latest investment was in EnaChip as part of their Unattributed VC on September 9, 2021.

CBI Logo

PCI Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/2/2021

Unattributed VC

EnaChip

$7.1M

Yes

1

8/24/2021

Unattributed VC

Linnaeus Therapeutics

$4.34M

No

1

9/1/2019

Incubator/Accelerator

Cartio Therapeutics

Yes

1

2/11/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/7/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2021

8/24/2021

9/1/2019

2/11/2019

9/7/2018

Round

Unattributed VC

Unattributed VC

Incubator/Accelerator

Series B

Series A

Company

EnaChip

Linnaeus Therapeutics

Cartio Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$7.1M

$4.34M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.